Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: January-26-09
Credit Expiration Date: February-28-10

Faculty

David N. Neubauer, MD
Assistant Professor, Department of Psychiatry
Associate Director, Johns Hopkins Sleep Disorders Center
Johns Hopkins Bayview Medical Center
Baltimore, MD

Gary Owens, MD
President
Gary Owens Associates
Medical Management and Pharmaceutical Consulting
Glen Mills, PA

Credit Hours

Physician CME: 1.0
Pharmacist CE: 1.0 contact hour (0.10 CEU)
Nurse CE: 1.0 contact hour
Case Manager CE: 1 hour

Medium

Online Presentation

Program Description

Insomnia is a significant burden to the healthcare system, and many healthcare providers may not realize the extent to which insomnia affects patients. Insomnia is linked with decreased daytime alertness and performance, and there is an association with psychiatric conditions such as depression and anxiety. Compared with those who sleep well, patients with insomnia report more medical problems and physician office visits, are hospitalized twice as often, and use more medications. Depression, heart disease, body pain, and memory problems are associated with more prevalent symptoms of insomnia. Chronic insomnia may be associated with medical, neurologic, or psychiatric disorders. Other studies show an increase in absenteeism and higher accident rates. The socioeconomic impact of insomnia is also important; an economic analysis in 1994 estimated the total annual cost of insomnia at $92.5 to $107.5 billion. In 1999, investigators found that total cost for substances used to treat insomnia was $1.97 billion, and healthcare services for insomnia totaled $11.96 billion. A multi-site survey of various clinics revealed that insomnia is associated with increased healthcare resource use in enrollees of managed-care organizations. Healthcare providers and managed care decision makers need to understand the health and quality of life effects of insomnia and how to optimally utilize sleep medications in the managed care setting to minimize healthcare costs and maximize clinical outcomes.

Program Developer/Facilitator


.

Target Audience

Managed care medical directors, pharmacy directors, physicians, pharmacists, nurses, and case managers who care for patients with insomnia.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Summarize the cost burden that insomnia imposes upon medical insurance payors and how effective insomnia management may help reduce healthcare expenditures in patients with insomnia and related comorbidities
  2. Describe the effects of insomnia on medical and psychiatric comorbidities, such as hypertension, cardiovascular disease, and depression
  3. Differentiate safety and efficacy attributes associated with different hypnotic agents

Disclosures

It is the policy of NAMCP and ProCE, Inc., to ensure independence, objectivity, scientific rigor, and integrity in all of its continuing education activities. Faculty must disclose to program participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation.

Dr. Neubauer discloses that he has received honoraria for: serving as a consultant to Neurocrine Biosciences, Inc.; and serving as a consultant and speaker for sanofi-aventis U.S. and Takeda Pharmaceuticals North America, Inc.

Dr. Owens discloses that he has received honoraria for serving as a consultant to Wyeth Pharmaceuticals, Encysive Pharmaceuticals, Teva Pharmaceuticals, sanofi-aventis U.S., and Genzyme Corp.

Please note: The opinions expressed in this program should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this program may include the use of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental, and participants are advised to consult prescribing information and professional literature.

Credit Statements

Physicians: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the National Association of Managed Care Physicians (NAMCP) and Medical Communications Media, Inc. The NAMCP is accredited by the ACCME to provide continuing medical education to physicians.

NAMCP designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses: The American Association of Managed Care Nurses has been approved as a provider of continuing education by the Virginia Nurses Association (VNA). VNA is accredited as an approver of Continuing Education in nursing by the American Nurses Credentialing Center's Commission on Accreditation. 1.0 contact hour will be awarded to nurses who complete this activity.

Case Managers: This activity has been approved by the Commission for Case Manager Certification for requirements towards CCM renewal education. Approval number is CM474-A200.

Pharmacists:ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Program Number 221-999-09-012-H01-P has been assigned to this home-study CPE activity (initial release date 02-20-09). This CPE activity is approved for 1.0 contact hour (0.10 CEU) in states that recognize ACPE providers. The program is provided at no cost to participants. Statements of credit will be issued online upon completion of the program evaluation and the post-test with a score of 70% or higher. No partial credit will be given.

Commercial Support Statements

Supported through an educational grant from Takeda Pharmaceuticals North America, Inc.

Certificate Fee

$0.00

Disclaimer

©2009 Medical Communications Media, Inc. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational program are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, NAMCP, ProCE, Inc., or Takeda Pharmaceuticals North America, Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS